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Abstract
We previously reported two modes of development of acquired TRAIL resistance: early phase and
late phase [1]. In these studies, we observed that greater Akt activity and the expression of Bcl-xL
were related mainly to the late phase of acquired TRAIL resistance.
Recently we became aware of a possible mechanism of early phase TRAIL resistance development
through internalization and degradation of TRAIL receptors (DR4 and DR5). Our current studies
demonstrate that TRAIL receptors rapidly diminish at the membrane as well as the cytoplasm within
four hours after TRAIL exposure, but recover completely after one or two days. Our studies also
reveal that Cbl, a ubiquitously expressed cytoplasmic adaptor protein, is responsible for the rapid
degradation of TRAIL receptors; Cbl binds to them and induces mono-ubiquitination of these
receptors concurrent with their degeneration soon after TRAIL exposure, creating the early phase of
acquired TRAIL resistance.
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1. Introduction
TRAIL has been shown to induce apoptosis in a number of cancer cell lines while displaying
minimal or no toxicity to normal cells, suggesting that this protein may hold potential for
development as a new cancer therapeutic agent. However, although TRAIL is regarded as a
potential anticancer agent, considerable numbers of cancer cells, especially some highly
malignant tumors, are resistant to apoptosis induction by TRAIL, and some cancer cells that
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were originally sensitive to TRAIL-induced apoptosis can become resistant after repeated
exposures (acquired resistance) [2]. We observed that, for DU-145 prostate cancer cells with
acquired TRAIL resistance, there was greater Akt activity and expression of Bcl-xL [1].
TRAIL induces an apoptotic response in tumor cells by binding to TRAIL receptors. Four
distinct TRAIL receptors have been identified: TRAIL-R1/DR4, TRAIL-R2/DR5, TRAIL-R3/
DcR1, and TRAIL-R4/DcR2. These receptors have been classified into two groups: death-
inducing receptors (TRAIL-R1 and -R2) and death-inhibitory receptors (TRAIL-R3 and -R4)
[3,4]. Both TRAIL-R1 and TRAIL-R2 contain a C-terminal death domain that signals
downstream caspase activation to mediate TRAIL-induced apoptotic cell death in a variety of
tumor cells. In contrast to these death-inducing receptors, TRAIL-R3, and TRAIL-R4 are
death-inhibitory receptors, which share homology with the death-inducing TRAIL-R1 and
TRAIL-R2 but lack transmembrane and death domains or have a truncated, nonfunctional
death domain, respectively. The mechanism of protection by these death-inhibitory receptors
was postulated to involve competition for TRAIL or activation of antiapoptotic signals perhaps
via activation of NF-κB [5]; TRAIL-R4 cannot transmit a death signal but can weakly activate
NF-κB, which may protect cells from TRAIL-mediated apoptosis [6]. It is not fully clear how
widespread the decoy receptors’ surface expression in tumor or normal cells is, or how these
receptors modulate TRAIL signaling since the death-inhibitory receptors may undergo
relocation from the nucleus to the cytoplasm and cell membranes [7,8]. A fifth receptor,
osteoprotegerin, exists in a secreted form and appears to inhibit TRAIL-induced apoptosis by
competitive inhibition of the binding of TRAIL to the death receptors TRAIL-R1 and -R2
[9].
Recently, Kohlhaas et al. [10] reported that endocytosis of TRAIL and its receptors occurred
rapidly in a time- and concentration-dependent manner; this suggests a means of TRAIL
activity reduction since down regulation of activated receptors reduces constitutive signaling
[11]. Many studies about the endocytosis and subsequent degradation of the receptors have
been done with receptor tyrosine kinases (RTKs) [12,13]. RTK ubiquitination has been known
to be important for both receptor internalization and degradation in the lysosome [12,14]. In
the yeast Saccaromyces cerevisiae, ubiquitin molecules conjugated to lysine residues of
membrane proteins function as endocytosis motifs [15], and mono-Ub (ubiquitin) signals
appear to play an evolutionally conserved role in the endosomal sorting of internalized
activated receptors for degradation in the lysosome [14] However, under certain physiological
conditions, it has been reported that Ub-independent mechanisms can promote epidermal
growth factor (EGF) receptor internalization [16,17]. In this case, endocytosis of membrane
proteins is typically mediated by signals present in their cytoplasmic domains [18]. Once
internalized, the ligand-receptor complex is targeted to early endosomes and the receptor is
then either recycled to the cell surface or directed to lysosomes for degradation [19]. In the
case of cytosolic and nuclear proteins, polyubiquitin chains are usually added to them for
degradation via the proteosome [20].
Cbl is a well known multi-adaptor protein involved in ligand-induced downregulation of
receptor tyrosine kinases [21]. The Cbl family of adaptor proteins comprises three mammalian
members: c-Cbl, Cbl-b, and Cbl-3. These proteins serve as E3 ubiquitin ligases targeting
signaling proteins, such as activated protein tyrosine kinases, to the proteosome or lysosome
for degradation [22]. Cbl ubiquitin-protein ligases are modular proteins that contain a
conserved N-terminal tyrosine kinase binding (TKB) domain and RING finger domain in
addition to other protein interaction motifs [23]. The TKB domain interacts with specific
phosphotyrosine residues on RTKs directly, or through phosphotyrosine residues on adaptors
indirectly [24,25]; the consensus sequence for recognition by the Cbl TKB domain is NXpY
(S/T)XXP. In this study, we observed that c-Cbl interacts with TRAIL receptors and regulates
the level of TRAIL receptors through the proteosomal and lysosomal pathways. The
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differential role of c-Cbl in these two different degradation pathways is probably determined
by the phosphorylation status of c-Cbl at the Tyr-731 residue. We also observed that TRAIL-
stimulated c-Cbl-mediated-ubiquitination of TRAIL receptors is responsible for the early phase
of acquired TRAIL resistance.
2. Materials and Methods
2.1. Cell culture and survival assay
Human prostate adenocarcinoma DU-145 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA) and 26
mM sodium bicarbonate for monolayer cell culture. The cells were maintained in a humidified
atmosphere containing 5% CO2 and air at 37° C.
2.2. Reagents and antibodies
MG-132, lactacystin and biotin-X-NHS were purchased from Calbiochem (San Diego, CA,
USA). Amantadine was purchased from Sigma-Aldrich (St. Louis, MO, USA). Monoclonal
anti-DR4 and anti-DR5 were purchased from Alexis Biochemicals. Polyclonal anti-DR4, anti-
DR5, monoclonal/polyclonal anti-Ub and protein G-agarose were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Monoclonal anti-Ub and polyclonal anti-c-Cbl
were purchased from Cell Signaling Technology, Inc. (Beverly, CA, USA). Monoclonal anti-
PARP was purchased from Biomol International, L.P. (Plymouth Meeting, PA, USA).
Monoclonal anti-HA (clone 3F10) was purchased from Roche Applied Science (Indianapolis,
IN, USA). Monoclonal anti-actin was purchased from ICN (Costa Mesa, CA, USA).
2.3. Immunofluorescence
After TRAIL treatment for 4 h, DU-145 cells were fixed with 1 % formaldehyde in PBS for
20 min in ice, and permeabilized for 10 min at room temperature with PBS containing 1 %
BSA and 0.1 % Triton-X-100. After washing twice with cold PBS, the cells were blocked in
1 % BSA, 10 % rabbit serum for 1 h at room temperature. They were then incubated with goat
DR4 antibody having an epitope mapping at the C-terminus (C-20, Santa Cruz, 1:50 dilution)
for 1 h at room temperature, followed by three washes with cold PBS. Samples were then
incubated with secondary antibody (rabbit Alexa Fluor 555 anti-goat antibody 1:100) for 1 h
at room temperature. After washing three times with cold PBS and after mounting with
mounting solution, the slides were observed under the fluorescence microscope.
2.4. RNA interference by siRNA c-Cbl
To construct siRNA of c-Cbl, pSilencer 2.1-U6 hygro vector (Ambion, Inc., Austin, TX, USA)
was used for expressing siRNA for c-Cbl. The insert for hairpin siRNA into pSilencer was
prepared by annealing two oligonucleotides. For human c-Cbl siRNA, the top strand sequence
was 5’-
GATCCGATGGAGACACTTGGAGAATTCAAGAGATTCTCCAAGTGTCTCCATCTT
TTTTG GAAA-3’, and the bottom strand sequence was 5’-
AGCTTTTCCAAAAAAGATGGAGACACTTGGAGAATCTCTTGAATTCTCCAAGTG
TCTCC ATCG-3’. The annealed insert was cloned into pSilencer 2.1-U6 hygro digested with
BamH I and Hind III. The correct structure of pSilencer 2.1-U6 hygro-c-Cbl was confirmed
by nucleotide sequencing. The resultant plasmid, pSilencer-c-Cbl, was transfected into DU-145
cells. The interference of c-Cbl protein expression was confirmed by immunoblot using anti-
c-Cbl antibody (Cell Signaling).
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2.5. Protein extracts and polyacrylamide gel electrophoresis
Cells were lysed with 1 × Laemmli lysis buffer (2 % sodium dodecyl sulfate, 10 % glycerol,
0.002 % bromophenol blue, 62.5 mM Tris, pH 6.8) and boiled for 10 min. Protein content was
measured with BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). The samples were
diluted with 1 × lysis buffer and added β-mercaptoethanol to be 350 mM, then equal amounts
of protein were loaded on 10 % or 15 % sodium dodecyl sulfate (SDS)-polyacrylamide gels.
SDS-PAGE analysis was performed according to Laemmli using a Hoefer gel apparatus.
2.6. Immunoblot analysis
Proteins were separated by SDS-PAGE and electrophoretically transferred to nitrocellulose
membrane. The nitrocellulose membrane was blocked with 5 % nonfat dry milk in PBS-
Tween-20 (0.1 %, v/v) at 4° C overnight. The membrane was incubated with primary antibody
(diluted according to the manufacturer’s instructions) for 2 h. Horseradish peroxidase
conjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody. Immunoreactive
protein was visualized by the chemiluminescence protocol (ECL, Amersham, Arlington
Heights, IL, USA).
2.7. Biotin labeling to plasma membrane
After TRAIL treatment for the indicated time, DU-145 cells were washed with ice-cold PBS
and incubated with 0.5 mg/ml biotin-X-NHS dissolved in a borate buffer (10 mM boric acid,
150 mM NaCl, pH 8.0) for 45 min at 4°C. Biotin coupling was terminated by washing the
plates with ice-cold PBS containing 15 mM glycine. After washing with room temperature
PBS, proteins were lysed for the immunoprecipitation with mouse anti-DR4 or DR5 antibody
(Alexis). Protein biotinylation was detected by peroxidase conjugated streptavidin after
western blotting.
2.8. Site-directed mutagenesis
The QuickChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) was
used to make point mutations in human Cbl protein. One tyrosine residue in Cbl (Tyr-371 Cbl)
was replaced with phenylalanine (Phe-371 Cbl). Sense primer (5’-
CAGGAACAATATGAATTATTCTGTGAGATGGGCTCCAC-3’) and antisense primer
(5’-GTGGAGCCCATCTCACAGAATAATTCATATTGTTCCTG-3’) were used for site-
directed mutagenesis. PCR reaction was prepared by adding 5 μl of 10X reaction buffer, 20
ng of dsDNA template (pSRα neo-HA-Cbl was kindly provided by Dr. Langdon (University
of Western Australia, Australia)), 125 ng of each sense primer, 125 ng of each antisense primer,
1 μl of deoxyribonucleotide triphosphate mix, 3 μl QuickSolution, double-distilled water to a
final volume of 50 μl, and 1 μl of Pfu Turbo DNA polymerase (2.5 U/μl). PCR was performed
with 18 cycles (95° C for 1 min; 57° C for 1 min; 68° C for 12 min) with initial incubation at
95° C for 2 min. Following temperature cycling, the reaction was placed on ice for 2 min to
cool the reaction. After PCR, 1 μl of Dpn I restriction enzyme (10 U/μl) was added directly to
each amplification reaction and incubated at 37° C for 1 h to digest the parental supercoiled
dsDNA. The Dpn I-treated dsDNA was transformed into Epicurian coli XL1-Blue
supercompetent cells. Colonies were selected and the resultant plasmid was sequenced using
primer (5’-GGCTGAGCTGTACTCGTCTG-3’) to confirm mutation.
2.9. Confocal microscope studies
To detect the localization of DR4 and c-Cbl, 1 × 105 tumor cells were seeded overnight on
glass slides in 37° C and 5% of CO2. Next, the culture media was replaced by a fresh one
supplemented with TRAIL (200 ng/ml). After 2 h of co-incubation with TRAIL, cells were
washed in 0.5% BSA in PBS, fixed in 2% paraformaldehyde for 15 min, permeabilized with
0.05% Triton-X, washed and blocked with 2% BSA in PBS for 45 min to eliminate non-specific
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binding of secondary Abs. The following Abs were used for staining: polyclonal goat anti-
human DR4 (C-20, Santa Cruz Biotechnology) and polyclonal rabbit anti-human c-Cbl (Cell
Signaling). Primary Abs were diluted 1:100-1:200 in 0.5% BSA and incubated 1 h in moist
chamber, then washed and incubated with secondary Abs. As a secondary Abs, donkey anti-
goat TexasRed-labeled (Santa Cruz Biotechnology) and donkey anti-rabbit FITC-labeled
(Santa Cruz Biotechnology) were used at dilution 1:500 and incubated 45 min in moist chamber
and in the dark. Control reactions included replacement of primary antibody by 0.5% BSA.
Slides were mounted in a medium with 4’, 6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories) in order to trace cell nuclei. Cells were visualized in 0.4-μm sections using an
inverted Olympus Fluoview 1000 laser scanning confocal microscope under a × 60 oil
immersion objective. For digital image analysis, the software Adobe Photoshop 7.0 version
was used.
2.10. In vitro ubiquitination assay
DU-145 cells were transfected with HA-tagged Cbl plasmid (pSRα neo-HA-Cbl). The cells
were lysed with lysis buffer, and the lysate was immunoprecipitated with anti-HA antibody
and collected with protein G plus agarose. Ubiquitination was carried out with HA-tagged Cbl
as a potential E3 ligase in a 20 μl reaction solution (Biomol, 10 × buffer, IPP (20 U/ml), DTT
1 mM, Mg-ATP 5 mM, 20X E1 0.1 μM, Flag-Ub (2.5 μM), GST-DR4, UbcH7 as E2
conjugating enzyme 0.2 mg/ml) at 37 ° C for 1 h. Samples were analyzed by electrophoresis
on 15 % SDS-PAGE followed by immunoblotting with anti-ubiquitin antibody (Cell
Signaling). For the purification of DR4 as a target protein of ubiquitination, cytoplasmic
domain of DR4 was subcloned into BamHI/XhoI site of pGEX4T-1 after PCR of cytoplasmic
domain of DR4 by using pCMV1FlagDR4 as a template. pCMV1FlagDR4 was kindly
provided by Dr. Vincenz at the University of Michigan. Sense primer was 5’-
CATAGGATCCGGCTCAGGTTGTGGAGGGGAC-3’, and antisense primer was 5’-
CAGTCTCGAGTCACTCCAAGGACACGGCAGAGCC-3’. pGEX-4T-1/DR4 was
transformed into JM109, and expressed DR4 corresponding to cytoplasmic domain was
purified by using glutathione-Sepharose 4B (Amersham).
3. Results
3.1. Correlation between development and decay of acquired TRAIL resistance and down
regulation of TRAIL receptors (DR4, DR5) at the early phase of acquired TRAIL resistance
Previous studies have shown that apoptotic signals of TRAIL are transduced by binding to the
TRAIL receptors DR4 and DR5 [8,26,27]. In this study, we hypothesized that TRAIL receptors
also play a role in the development of acquired TRAIL resistance, in particular early phase,
through their internalization and degradation after ligand-receptor complex formation. To test
the hypothesis, we first examined whether the level of surface TRAIL receptors is reduced
after TRAIL treatment. For this study, we labeled accessible lysines of surface receptors by
using the water-soluble, membrane-impermeant biotin-X-NHS. Data from measurement of
TRAIL-induced cytotoxicity show that acquired TRAIL resistance developed immediately and
was sustained for 2 days and then gradually decayed (upper panel in Fig. 1A). These
observations were consistent with poly(ADP-ribose) polymerase (PARP) cleavage, which is
the hallmark feature of apoptosis (lower panel in Fig. 1A). In the next step, we examined the
level of total TRAIL receptors or membrane-bound TRAIL receptors immediately or at various
times (1–6 days) after treatment with 200 ng/ml TRAIL for 4 h (Figs. 1B and 1C). The level
of total and membrane-bound TRAIL receptors decreased rapidly and recovered within 1 or 2
days for DR5 or DR4, respectively (Figs. 1B and 1C). Similar results were observed with
human pancreatic cancer MiaPaCa-2 cells (data not shown). We further examined the time
course of acquired TRAIL resistance development within 1 day (early phase) and changes in
the level of TRAIL receptors during treatment with 200 ng/ml TRAIL. Figure 2A shows that
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acquired TRAIL resistance developed immediately after TRAIL treatment and was sustained
for 24 h. Data from western blot analysis demonstrate that the levels of total and membrane-
bound TRAIL receptors were rapidly decreased within 2 h during treatment with TRAIL (Figs.
2B and 2C). The reduction of membrane-bound DR4 and DR5 during TRAIL treatment was
confirmed by using the fluorescence microscope (DR4 only) (Fig. 2D). These results suggest
that resistance to secondary TRAIL treatment immediately after TRAIL treatment is related to
the reduction of TRAIL receptors at the membrane in what is called desensitization of receptors.
3.2. Monoubiquitination of TRAIL receptors (DR4, DR5)
As shown in Figures 2B and 2C, downregulation of TRAIL receptors (DR4 and DR5) was
observed during TRAIL treatment. Several researchers previously reported that membrane
receptor kinases are usually monoubiquitinated for endocytic trafficking both at the stage of
receptor internalization at the plasma membrane and also in the endosomal compartment,
where ubiquitinated receptors are sorted to a lysosomal compartment [16, 17]. In our current
study, we investigated whether ubiquitination occurs during downregulation of TRAIL
receptors. Figures 3A and 3B clearly demonstrate that DR4 and DR5 were monoubiquitinated
during TRAIL treatment. Chloropromazine, an internalization inhibitor, inhibits TRAIL-
induced ubiquitination of DR4 (data not shown). These results suggest that ubiquitination of
TRAIL receptors occurs after internalization.
3.3 Interaction of TRAIL receptors with c-Cbl during TRAIL treatment
A fundamental question that still remains unanswered is how TRAIL receptors are
ubiquitinated during treatment with TRAIL. We hypothesized that c-Cbl, an E3 ubiquitin
ligase, is involved in the ubiquitination of TRAIL receptors. To examine this possibility, first
of all, we investigated whether c-Cbl interacts with TRAIL receptors during TRAIL treatment.
Data from immunoprecipitation analysis in Figures 4A and 4B clearly show that interactions
between c-Cbl and TRAIL receptors (DR4/DR5) occurred during TRAIL treatment. To
confirm our observations, we employed an immunofluorescent staining analysis with confocal
microscope. The immunofluorescent staining studies also demonstrate the interaction between
c-Cbl and DR4 during treatment with 200 ng/ml TRAIL for 2 h (Fig. 4C). For the confirmation
of biological function of c-Cbl as an E3 ligase, an in vitro ubiquitination assay was performed
by using HA-tagged c-Cbl as a potential E3 ligase for DR4 during TRAIL treatment. Results
from Figure 4D clearly demonstrate direct E3 ligase activity of c-Cbl towards TRAIL receptors.
3.4. Involvement of c-Cbl in TRAIL receptor degradation but not in internalization
After observation of c-Cbl involvement in the reduction of TRAIL receptors during TRAIL
treatment, we further investigated the biological role of c-Cbl in the reduction of TRAIL
receptors by using the siRNA technique for c-Cbl knockdown. To make a stable cell line of
siRNA of c-Cbl, the sequences for siRNA of c-Cbl were inserted into pSilencer 2.1-U6 hygro
vector and then DU-145 cells were stably transfected with this expression vector. After
hygromycin B-resistant cell clones were isolated, the interference to c-Cbl protein expression
was verified by immunoblotting assay using anti-c-Cbl antibody. We obtained several stable
transfectants and chose 3 clones (si c-Cbl #1, #3, #4) in which c-Cbl expression was almost
completely repressed (Fig. 5A). In the first step of our siRNA analysis, we examined whether
c-Cbl knockdown alters TRAIL sensitivity. Figure 5B shows that a pool of si c-Cbl clones in
comparison to pSilencer control plasmid transfectant was more sensitive to TRAIL
cytotoxicity, but not to another apoptotic agent, cisplatin, cytotoxicity. These results suggest
that the increase in sensitivity seen in c-Cbl-depleted cells is specific to TRAIL-induced
apoptosis. TRAIL-induced morphological alterations and cell death were increased in the pool
of si c-Cbl clones (Fig. 5B). This is probably due to an increase in the level of TRAIL receptors
(DR4 and DR5) in c-Cbl knockdown cells (Figs. 5C and 5D). Interestingly, the reduction of
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membrane-bound TRAIL receptors during TRAIL treatment was almost the same in the
pSilencer control plasmid transfectant and a pool of si c-Cbl clones (Figs. 5C and 5D).
However, the reduction of total TRAIL receptors was inhibited in c-Cbl knockdown cells (Figs.
5C and 5D). These data suggest that c-Cbl is involved in the degradation of TRAIL receptors,
but not in the internalization. To understand the increased level of DR4 and DR5 at the
membrane and total lysates in c-Cbl knockdown cells, we further investigated the possibility
that, without TRAIL treatment, c-Cbl is involved in the steady-state turnover of total DR4 and
DR5 by the proteosomal degradation pathway. To test the hypothesis, cells were treated with
proteosome inhibitors, MG-132 and/or lactacystin. The levels of DR4 and DR5 were
significantly increased by treatment with MG-132 and/or lactacystin (lanes 3, 5, and 7 in Fig.
5E). However, the levels of DR4 and DR5 were decreased by treatment with TRAIL even in
the presence of MG-132 and/or lactacystin (lanes 4, 6, and 8 in Fig. 5E). These data suggest
that the reduction of DR4 and DR5 levels during treatment with TRAIL is not mediated through
the proteosomal degradation pathway. Figure 5E also shows that proteosome inhibitors
enhanced PARP cleavage. This increase in sensitivity to TRAIL is probably due to an increase
in DR4 and DR5 levels. To examine whether the lysosomal pathway is involved in TRAIL
receptor regulation during TRAIL treatment, cells were pretreated with amantadine, a lysosome
inhibitor prior to TRAIL treatment. Figure 5F shows that inhibition of the lysosomal pathway
prevented the reduction of DR5 during TRAIL treatment. To examine the role of proteosomal
and lysosomal pathways in the development of acquired TRAIL resistance, the effect of
proteosome inhibitor and lysosome inhibitor on the development of acquired TRAIL resistance
was assessed. Cells were pretreated with MG-132 and/or amantadine and treated with 20 ng/
ml TRAIL and/or 50 ng/ml TRAIL, respectively. These concentrations of TRAIL are the
isosurvival doses to 200 ng/ml TRAIL in the control cells. Acquired TRAIL resistance was
evaluated by challenging TRAIL treatment. Figure 5G shows that MG-132 and amantadine
effectively inhibited the development of acquired TRAIL resistance. To investigate the role of
c-Cbl in the development of acquired TRAIL resistance, c-Cbl knockdown cells were treated
with 20 ng/ml TRAIL, which is the isosurvival dose to 200 ng/ml TRAIL in the pSilencer
control plasmid transfectant. As shown in Fig. 5H, development of acquired TRAIL resistance
was partially suppressed in c-Cbl knockdown cells. Moreover, acquired TRAIL resistance
rapidly decayed in c-Cbl knockdown cells. To examine whether the rapid decay of acquired
TRAIL resistance in c-Cbl knockdown cells is due to the recovery of TRAIL receptors,
membrane-bound and total level of TRAIL receptors were determined at various times after
TRAIL treatment. Figures 5I and 5J clearly demonstrate that the levels of membrane DR4 and
DR5 were recovered to their original levels faster in c-Cbl knockdown cells compared to
pSilencer control plasmid transfected cells.
3.5. Monoubiquitination of TRAIL receptors is dependent on c-Cbl
We observed that c-Cbl plays an important role in the reduction of TRAIL receptors and
development of acquired TRAIL resistance during treatment with TRAIL. We also observed
that ubiquitination of TRAIL receptors occurs during TRAIL treatment. Based on our
observations, we hypothesized that c-Cbl which is known as an E3 ubiquitin ligase is involved
in monoubiquitination of TRAIL receptors. As shown in Figures 6A and 6B,
monoubiquitination of TRAIL receptors (DR4, DR5) decreased in c-Cbl knockdown cells,
suggesting that c-Cbl is involved in ubiquitination of TRAIL receptors during TRAIL
treatment.
3.6. Phosphorylation of tyrosine 371 residue of c-Cbl is important for ubiquitination of TRAIL
receptors
Several researchers have reported that various membrane receptors are internalized by
ubiquitin ligase c-Cbl to achieve efficient receptor down-regulation [12]. It is well known that
c-Cbl is inducibly phosphorylated by receptor and non-receptor protein tyrosine kinases, but
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constitutively phosphorylated by oncogenic tyrosine kinases in various cancer cell lines [28].
The bulk of phosphorylation occurs at the carboxy terminus of c-Cbl which contains multiple
tyrosine residues [29–31]. Phosphorylation of Y700, Y731, and Y774 is necessary for the c-
Cbl-CIN85 interaction, which mediates endocytosis and downregulation of EGFR [32];
especially, phosphorylation of Y731 of c-Cbl provides a docking site for downstream signaling
components such as p85 and Fyn [33,34]. Phosphorylation of Y371 regulates the transfer of
ubiquitin from UbcH7 to the substrate [22,35,36]. In this study, we hypothesized that Y371 of
c-Cbl plays an important role in the downregulation of TRAIL receptors. To test the hypothesis,
tyrosine of 371 was replaced with phenylalanine by site-directed mutagenesis technique. We
examined whether ubiquitination of TRAIL was affected by overexpression of mutant-type c-
Cbl (Y371F Cbl). Overexpression of Y371F Cbl inhibited reduction of total (not membrane)
DR4 and DR5 (Figs. 6C and 6E) and ubiquitination of DR4 and DR5 (Figs. 6D and 6F) during
TRAIL treatment. Overexpression of Y371F Cbl also facilitated the decay of acquired TRAIL
resistance (Fig. 6G). These results suggest that phosphorylation of Y371 of c-Cbl is important
for ubiquitination of TRAIL receptors and the early phase of acquired TRAIL resistance.
Discussion
We have previously shown that TRAIL treatment induces acquired TRAIL resistance in two
modes; one is the restoration of biological function of Bcl-xL, and the other is the elevation of
the Bcl-xL level [1]. The former mode has been proven to have an important role in the
development of acquired TRAIL resistance in the early phase; the latter mode is responsible
for the late phase of acquired TRAIL resistance. In the present study, we observed that the
downregulation of TRAIL receptors after TRAIL treatment is also involved in the development
of acquired TRAIL resistance, particularly in the early phase. Kohlhaas et al. [10] has reported
that, unlike CD95 and TNF-R1-induced apoptosis, rapid endocytosis of TRAIL and its
receptors is not required for TRAIL-induced apoptosis [37,38]. Thus, a question that remains
unanswered is the biological meaning of internalization and degradation of TRAIL receptors
during TRAIL treatment. In this study, we mainly focused on TRAIL death receptors (DR4,
DR5) because decoy receptors were not well detected in DU-145 cells (data not shown). These
observations are consistent with previous report that little DcR expression was frequently
observed in cancer cells [39]. Also, DcR expression does not appear to be correlated with
resistance to TRAIL [39].
As shown in Figure 2, the level of TRAIL receptors rapidly decreased at the membrane as well
as in the whole cell within 4 h during TRAIL treatment, and the reduction of TRAIL receptors
coincided with the acquisition of early phase TRAIL resistance. However, acquired TRAIL
resistance is still sustained 24 h after TRAIL treatment although the total level of DR5 was
recovering during that time (Fig. 1C). These results suggest that the early phase (within 24 h
after TRAIL exposure) of acquired TRAIL resistance was contributed by other factors in
addition to the reduction of TRAIL receptors, such as the restoration of biological activity of
Bcl-xL [1]. Nevertheless, the reduction of TRAIL receptors is a major factor in the development
of acquired TRAIL resistance (Fig. 5).
Our studies reveal that rapid degradation following internalization of TRAIL receptors occurs
during treatment with TRAIL. Our studies also reveal that ubiquitination of TRAIL receptors
is responsible for degradation, but not internalization. These observations somewhat contradict
previous reports. In the case of RTKs, recent studies illustrate that RTKs are monoubiquitinated
at multiple sites following ligand stimulation and that ubiquitin acts as a signal controlling
receptor internalization and routing to the lysosome for degradation [16,17,40], and c-Cbl, an
E3 ubiquitin ligase, is involved in RTK ubiquitination [41–43]. We observed that c-Cbl was
also involved in the monoubiquitination of TRAIL receptors (DR4, DR5) during TRAIL
exposure (Figs. 6A, 6B). However, unlike its role in RTKs, monoubiquitination by c-Cbl is
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found to be necessary for degradation of TRAIL receptors rather than internalization (Figs.
5C, 5D). These results are similar to previous observations that Cbl mutants impaired in their
ubiquitin ligase activity block receptor degradation by shunting endocytosed receptors from
the endosome to the recycling pathway and not by blocking receptor internalization [43], and
Cbl-mediated ubiquitination of EGFRs in mouse embryonic fibroblasts is required for
endosomal receptor sorting and degradation but is dispensable for receptor internalization
[41]. Observations from Levkowitz et al. [43] are consistent with our observations that
downregulation of c-Cbl leads to an increase in the level of DR4 and DR5 at the membrane
(Figs 5C and 5D) and facilitation of restoration of TRAIL receptors (Figs. 5I and 5J).
As pointed out by Haglund et al. [16,17], c-Cbl mediated ubiquitination of TRAIL receptors
at the cellular membrane is not essential for internalization because of the existence of multiple
internalization pathways. Nonetheless, c-Cbl-mediated ubiquitination of TRAIL receptors has
a main role in the endosomal sorting leading to the degradative pathway (Figs. 6A, 6B, 6D,
6F). The inhibition of c-Cbl-induced ubiquitination would impair endosomal sorting and
lysosomal degradation, but not the internalization step [20]. Höller and Dikic [14] suggested
that the mechanism underlying ligand-dependent receptor endocytosis seems to be divergent
and more complex in mammalian cells, which means endocytosis is not regulated by one
exclusive pathway but is, instead, covered by several redundant mechanisms.
Results from our studies strongly suggest that phosphorylation of the tyrosine 371 residue of
c-Cbl plays an important role in the activation of E3 ubiquitin ligase activity of c-Cbl. A
fundamental question that remains is how c-Cbl is phosphorylated during TRAIL treatment.
Interestingly, TRAIL receptors do not contain phosphotyrosine residue consensus recognition
sites, suggesting that the presence of non-receptor tyrosine kinase as an adaptor to
phosphorylate TRAIL receptors and Cbl is plausible. TKB domain of c-Cbl could be recruited
to non-receptor tyrosine kinase instead of TRAIL receptors. This possibility is being
investigated, calling for the detection of responsible non-receptor tyrosine kinase to
phosphorylate TRAIL receptors and c-Cbl. In addition to this possibility, the fact that
internalization of TRAIL receptors is not interrupted in c-Cbl knockdown cells raises a
possibility that other endocytosis motifs might be present in TRAIL receptors and that these
motifs might function in an ubiquitin-independent manner. We believe that this model will
provide a framework for future studies.
Acknowledgments
This work was supported by the following grants: NCI grant funds (CA95191, CA96989 and CA121395: J. J. S., Y.J.
L.) and (CA113263: M.A.A., D.L.B., Y.J. L.), DOD prostate program funds (PC020530 and PC040833), Susan G.
Komen Breast Cancer Foundation fund (BCTR60306), and Samuel & Emma Winters Foundation, and this research
was also supported by Basic Science Research Program through the National Research Foundation of Korea (NRF)
funded by the Ministry of Education, Science and Technology (2009-0071809; J.J. Song) and a faculty research grant
of Yonsei University College of Medicine for 2009-0113; J.J. Song). a grant from the Ministry of Commerce, Industry,
and Energy of Korea (990-14-05, to J-H. Kim).
Abbreviations
TRAIL tumor necrosis factor-related apoptosis-inducing ligand
DR4 5, death receptor4, 5
PAGE polyacrylamide gel electrophoresis
PBS phosphate-buffered saline
SDS sodium dodecyl sulfate
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Figure 1. TRAIL-induced development of acquired TRAIL resistance and alteration of levels of
TRAIL receptors (DR4, DR5) in DU-145 cells (long term)
(A) Cells were first treated with TRAIL (200 ng/ml) for 4 h and then detached cells were
removed by washing out with PBS. After removal of detached cells, fresh media was added
onto the remaining attached cells and incubated for the time indicated (1–6 d), replenishing
with fresh media every day, and then cells were treated a second time with TRAIL (200 ng/
ml) for 4 h. Cell survival was determined by trypan blue exclusion assay (upper panel) and cell
lysates were subjected to immunoblotting for PARP or actin (lower panels). Con, untreated
control cells. Error bars represent the S.E. from three separate experiments. (B and C) Cells
were treated with TRAIL (200 ng/ml) for 4 h and then detached cells were removed by washing
out with PBS. After removal of detached cells, fresh media was added onto the remaining
attached cells and incubated for the time indicated (0 h, or 1–6 d), and then cells were treated
with biotin-X-NHS (0.5 mg/ml) following washing with PBS. After labeling with biotin, cell
lysates were immunoprecipitated with anti-DR4 or anti-DR5 antibody. Membrane-bound DR4
or DR5 was detected with peroxidase-conjugated streptavidin. Total DR4 or DR5 was detected
with anti-DR4 or anti-DR5 antibody, respectively (B, C).
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Figure 2. TRAIL-induced development of acquired TRAIL resistance, alteration of levels of TRAIL
receptors (DR4, DR5), and internalization of DR4 in DU-145 cells (short term)
(A) Cells were first treated with TRAIL (200 ng/ml) for 4 h and then detached cells were
removed by washing out with PBS. After removal of detached cells, fresh media was added
onto the remaining attached cells and cells were incubated for the time indicated (0 h, 4 h, 8
h, 12 h, 24 h), and then treated a second time with TRAIL (200 ng/ml) for 4 h. Cell survival
was determined by trypan blue exclusion assay (upper panel) and cell lysates were subjected
to immunoblotting for PARP or actin (lower panels). Con, untreated control cells. Error bars
represent the S.E. from three separate experiments. (B and C) Cells were treated with TRAIL
(200 ng/ml) for various times (10 min, 30 min, 1 h, 2 h, 3 h, 4 h). After detached cells were
removed, cells were treated with biotin-X-NHS (0.5 mg/ml). After labeling with biotin, cell
lysates were immunoprecipitated with anti-DR4 or anti-DR5 antibody of Alexis, respectively.
Membrane-bound DR4 or DR5 was detected with peroxidase-conjugated streptavidin. Total
DR4 or DR5 was detected with anti-DR4 (H-130) or anti-DR5 (N-19) antibody of Santa Cruz,
respectively. (D) Internalization of DR4 was determined by immunofluorescent staining as
described in “Materials and Methods”. Arrows indicate the localization of DR4.
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Figure 3. Ubiquitination of TRAIL receptors (DR4, DR5) during TRAIL treatment in DU-145 cells
Cells were treated with TRAIL (200 ng/ml) for various times. Cell lysates were
immunoprecipitated with anti-Ub antibody and immunoblotted with anti-DR4 (H-130)
antibody (A) or anti-DR5 antibody (N-19) (B) (upper panels). Cell lysates were
immunoprecipitated with anti-DR4 antibody (HS-101, Alexis) (A) or anti-DR5 antibody
(HS-201, Alexis) (B) and then immunoblotted with anti-Ub antibody (lower panels).
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Figure 4. Interaction between c-Cbl and TRAIL receptors during TRAIL treatment in DU-145
cells
Cells were treated with TRAIL (200 ng/ml) for various times and then cell lysates were
immunoprecipitated with anti-DR4 (A) or anti-DR5 (B) antibody and immunoblotted with
anti-c-Cbl, anti-DR4 or anti-DR5 antibody (upper panels). The presence of c-Cbl or actin in
the lysates was verified by immunoblotting (lower panels). (C) Cells were untreated (control)
or treated with TRAIL (200 ng/ml) for 2 h and stained with anti-DR4 (red) and anti-c-Cbl
(green) antibodies. Nuclei were stained with DAPI (blue). a, DR4 is expressed mainly on cell
membrane; b, c-Cbl shows the cytoplasm localization; c, overlay (a) and (b) showing no co-
localization of DR4 and c-Cbl in cytoplasm; d, DR4 is translocated to cytoplasm during
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treatment with TRAIL; e, c-Cbl is expressed in cytoplasm; f, figures (d) and (e) are overlaid
showing co-localization of DR4 and c-Cbl in cytoplasm (yellow) (arrows). (D) Cells were
transfected with pSRα neo-HA-Cbl and then untreated (lanes 1 and 2) or treated with TRAIL
(200 ng/ml) for 2 h (lane 3). Cell lystates were immunoprecipitated with mock IgG (lane 1) or
anti-HA antibody (lanes 2 and 3). In vitro ubiquitination assay was performed as described in
Experimental Procedures. Samples were immunoblotted with anti-Ub or anti-HA antibody
(upper panels). Cell lysates were immunoblotted with anti-HA antibody (lower panel).
Song et al. Page 16
Cell Signal. Author manuscript; available in PMC 2011 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Song et al. Page 17
Cell Signal. Author manuscript; available in PMC 2011 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Song et al. Page 18
Cell Signal. Author manuscript; available in PMC 2011 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Song et al. Page 19
Cell Signal. Author manuscript; available in PMC 2011 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. Role of c-Cbl in TRAIL sensitivity, level of TRAIL receptors (DR4, DR5), and
development of acquired TRAIL resistance in DU-145 cells
(A) Intracellular level of c-Cbl was examined in control vector transfected (pSilencer) or
pSilencer-si c-Cbl stably transfected single cell clones. (B) Control plasmid (si neg) or a pool
of pSilencer-si c-Cbl stably transfected clones (si c-Cbl pool) were treated with TRAIL (200
ng/ml) for 4 h or cisplatin (5 μg/ml) for 24 h and then morphological features were analyzed
with a phase-contrast inverted microscope (upper panels), or cell survival was determined by
tryphan blue exclusion assay (lower panel). Error bars represent the S.E. from three separate
experiments. (C and D) Control plasmid (si neg) or a pool of pSilencer-si c-Cbl stably
transfected (si c-Cbl pool) cells were treated with TRAIL (200 ng/ml) for 1 h or 2 h, and then
cells were treated with biotin-X-NHS (0.5 mg/ml) following washing with PBS. After labeling
with biotin, cell lysates were immunoprecipitated with anti-DR4 or anti-DR5 antibody.
Membrane-bound DR4 or DR5 was detected with peroxidase-conjugated streptavidin. Total
DR4 or DR was detected with anti-DR4 or anti-DR5 antibody, respectively (upper panels),
and cell lysates were subjected to immunoblotting for c-Cbl or actin (lower panels). (E) Cells
were pretreated with 10 μM MG132 and/or 10 μM lactacystin for 4 h followed by 200 ng/ml
TRAIL treatment for 4 h and then cell lysates were subjected to immunoblotting for PARP,
DR4 , DR5 or actin. (F) Cells were pretreated with 100 μM amantadine for 4 h followed by
200 ng/ml TRAIL treatment for 4 h. Cell lystates were immunoprecipitated with mock IgG or
anti-DR5 antibody and then immunoblotted with anti-DR5 antibody (upper panel). Cell lysates
were subjected to immunoblotting for actin (lower panel). (G) Lanes 2–5: Cells were treated
with TRAIL (200 ng/ml in lane 2, 20 ng/ml in lanes 3 and 5, 50 ng/ml in lane 4) for 4 h after
pretreatment with 10 μM MG132 (MG, lane 3), 100 μM amantadine (Ama, lane 4), or MG +
Ama (lane 5) for 4 h or without pretreatment (lane 2). Lanes 6–9: Cells were first treated as
described above and then detached cells were removed by washing out with PBS. After removal
of detached cells, fresh media were added onto the remaining attached cells and cells were
incubated for 1 day, and then treated a second time with TRAIL (200 ng/ml in lane 6, 20 ng/
ml in lanes 7 and 9, 50 ng/ml in lane 8) for 4 h after pretreatment with 10 μM MG (lane 7),
100 μM Ama (lane 8), or MG + Ama (lane 9) for 4 h or without pretreatment (lane 6). (H)
Control plasmid (si neg) or a pool of pSilencer-si c-Cbl stably transfected (si c-Cbl pool) cells
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were first treated with 200 ng/ml or 20 ng/ml TRAIL, respectively, for 4 h and then detached
cells were removed by washing out with PBS. After removal of detached cells, fresh media
were added onto the remaining attached cells and cell were incubated for the time indicated (0
h, 12 h, 24 h), and then treated a second time with TRAIL (200 ng/ml for si neg cells or 20 ng/
ml for si c-Cbl cells) for 4 h. Cell survival was determined by trypan blue exclusion assay
(upper panel) and cell lysates were subjected to immunoblotting for PARP or actin (lower
panels). Con, untreated control cells. Error bars represent the S.E. from three separate
experiments. (I and J) Control plasmid (si neg) or a pool of pSilencer-si c-Cbl stably transfected
(si Cbl pool) cells were first treated with 200 ng/ml or 20 ng/ml TRAIL, respectively, for 4 h
and then detached cells were removed by washing out with PBS. After removal of detached
cells, fresh media were added onto the remaining attached cells and cells were incubated for
the time indicated (0 h, 12 h, 24 h), and then cells were treated with biotin-X-NHS (0.5 mg/
ml) following washing with PBS. After labeling with biotin, cell lysates were
immunoprecipitated with anti-DR4 (I) or anti-DR5 (J) antibody. Membrane-bound DR4 or
DR5 was detected with peroxidase-conjugated streptavidin. Total DR4 or DR5 was detected
with anti-DR4 or anti-DR5 antibody, respectively (upper panels), and cell lysates were
subjected to immunoblotting for c-Cbl or actin (lower panels).
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Figure 6. Biological function of c-Cbl as an E3 ligase for the ubiquitination of TRAIL receptors
and the role of its ubiquitination activity in the development of acquired TRAIL resistance
(A and B) Control plasmid (si neg) or a pool of pSilencer-si c-Cbl stably transfected cells (si
c-Cbl pool) were treated with TRAIL (200 ng/ml) for 2 h, and then cell lysates were
immunoprecipitated with anti-Ub antibody and immunoblotted with anti-DR4 (A) or anti-DR5
(B) antibody (upper panels). Cell lysates were subjected to immunoblotting for c-Cbl or actin
(lower panels). (C and D) Cells were transfected with pSRα neo-HA-Cbl (wild type) or mutant
type (Y371F Cbl). Upper panels: After 48 h incubation, cells were treated with TRAIL (200
ng/ml) for 2 h, and then immunoprecipitated with anti-DR4 antibody after labeling with biotin
(C) or immunoprecipitated with anti-Ub antibody (D). Membrane-bound DR4 was detected
with peroxidase-conjugated streptavidin. Total DR4 was detected with anti-DR4 antibody.
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Ubiquitinated DR4 was detected with anti-DR4 antibody. Lower panels: Cell lysates were
subjected to immunoblotting for HA or actin. (E and F) Cells were transfected with pSRα neo-
HA-Cbl (wild type) or mutant type (Y371F Cbl). Upper panels: After 48 h incubation, cells
were treated with TRAIL (200 ng/ml) for 2 h, and then immunoprecipitated with anti-DR5
antibody after labeling with biotin (E) or immunoprecipitated with anti-Ub antibody (F).
Membrane-bound DR5 was detected with peroxidase-conjugated streptavidin. Total DR5 was
detected with anti-DR5 antibody. Ubiquitinated DR5 was detected with anti-DR5 antibody.
Lower panels: Expression of wild-type or mutant-type HA-Cbl was detected with anti-HA
antibody. (G) Cells were transfected with pSRα neo-HA-Cbl (wild type) or mutant type (Y371F
Cbl). After 48 h incubation, cells were first treated with TRAIL (200 ng/ml) for 4 h, and then
detached cells were removed by washing out with PBS. After removal of detached cells, fresh
media were added onto the remaining attached cells and cells were incubated for the time
indicated (0 h, 12 h, 24 h), and then treated a second time with TRAIL (200 ng/ml) for 4 h.
Cell survival was determined by trypan blue exclusion assay (upper panel) and cell lysates
were subjected to immunoblotting for PARP, HA-Cbl or actin (lower panels). Con, untreated
control cells. Error bars represent the S.E. from three separate experiments.
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